Risk assessment in diffuse large cell lymphoma at first relapse. A study by the Italian intergroup for Lymphomas

Haematologica

Volumn 86, Issue 9, 2001, Pages 941-950

  Guglielmi, C ^a   Martelli, M ^a   Federico, M ^a   Zinzani, P L ^a   Vitolo, U ^a   Bellesi, G ^a   Santini, G ^a   Tarella, C ^a   Zallio, F ^a   Pregno, P ^a   Di Renzo, N ^a   Resegotti, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adults; Lymphoma; Prognosis; Relapse; Transplantation

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MITOXANTRONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ITALY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HUMANS; ITALY; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 0034790340     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Ontology Group study
2. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial
3. m-BACOD treatment for intermediate and high grade malignant lymphomas: A Southwest Ontology Group phase II trial
4. Southwest ontology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas
5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
6. LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma
7. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
8. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
9. Results of MIME salvage regimen for recurrent or refractory lymphoma
10. ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
11. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP
12. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
13. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
14. Clinical, biological and histological features of late relapses in diffuse large cell lymphoma
15. Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH-84 regimen
16. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: Natural history of relapse after initial complete response and prognostic variables defining outcome aftrer relapse
17. Time to relapse has prognostic value in aggressive lymphoma enrolled in the Parma trial
18. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment
19. The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma
20. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
21. Time to relapse and age-adjusted IPI have independent prognostic value in aggressive lymphoma enrolled in the PARMA trial at first relapse
22. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer institute sponsored study of classifications of non-Hodgkin's lymphoma. Summary and description or a working formulation for clinical usage
23. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
24. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
25. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
26. Non parametric estimation from incomplete observations
27. Evaluation of survival data and two new rank order statistics arising in its consideration
28. Regression models and life tables
29. P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non Hodgkin's lymphoma
30. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group
31. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas
32. A new protocol (MiCEP) for the treatment of intermediate or high-grade non- Hodgkin's lymphoma in the elderly
33. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma. Long-term results of a multicenter study of the Italian lymphoma study group (GISL)
34. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL
35. MACOP-B treatment in diffuse large cell lymphoma: Identification of prognostic groups in an Italian Multicenter Study
36. Idarubicin in patients with diffuse large cell lymphoma: A randomized trial comparing VACOP-B (A=doxorubicin) vs VICOP-B (I=idarubicin)
37. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
38. Mutation of the p53 protein as a prognostic factor in aggressive B-cell lymphoma
39. Independent prognostic significance of a nuclear proliferation antigen in diffuse large-cell lymphoma as determined by the monoclonal antibody Ki-67
40. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group study
41. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins
42. BCL2 and other genomic alterations in the prognosis of large-cell lymphoma
43. 18q21 rearrangements in diffuse large cell lymphoma: Incidence and clinical significance
44. bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features
45. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases
46. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study
47. Prognostic significance of BCL2 protein expression and BCL2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
48. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma
49. Adhesion molecules in the prognosis of DLCL: Expression of a lymphocyte homing receptor (CD44), LFA-1 [CD11a/18), and ICAM-1 (CD54)
50. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
51. Relapse of intermediate or high-grade (unfavorable) non-Hodgkin's lymphoma as a low grade (favorable) non-Hodgkin's lymphoma. Report of four cases
52. High-grade non-Hodgkin's lymphoma relapsing as a low-grade follicular lymphoma: So-called downgraded lymphoma
53. Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma
54. Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen
55. Late relapse in patients with diffuse large cell lymphoma treated with MACOP-B
56. Therapeutic strategies for aggressive lymphomas
57. Relapsed lymphoma